J.P. Morgan Notebook Day 2: Walmsley On Diversity, Amgen's Overseas Cash, Growing Opdivo, Mylan On US Generic Pricing, Boston's Pipeline And J&J In Alzheimer's
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: GSK's Walmsley looks to be a leader on diversity, Amgen talks tax reform and deals, Mylan raises the issue of generic drug shortages, Boston builds out its pipeline, and J&J is dealing in Alzheimer's disease.
You may also be interested in...
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference in San Francisco: US corporate tax reform becomes a reality, Allergan's Saunders defends patent moves as a means of protecting jobs, clarity on generic prices from Teva, Biogen's money to burn, and making the most of FDA flexibility.
PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.